Logo

TWST

Twist Bioscience Corporation

TWST

Twist Bioscience Corporation • NASDAQ
$32.01 ▲ 0.98% (+0.31)
Market Cap $1.91 B
52w High $55.33
52w Low $23.30
Dividend Yield 0%
P/E -24.62
Volume 391.70K
Outstanding Shares 59.81M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $99.009M ▲ $80.772M ▼ $-26.978M ▼ -27.248% ▼ $-0.45 ▼ $-26.339M ▼
Q3-2025 $96.057M ▲ $81.417M ▼ $20.39M ▲ 21.227% ▲ $0.34 ▲ $26.381M ▲
Q2-2025 $92.793M ▲ $87.588M ▲ $-39.328M ▼ -42.383% ▼ $-0.66 ▼ $-32.606M ▼
Q1-2025 $88.713M ▲ $77.484M ▲ $-31.594M ▲ -35.614% ▲ $-0.53 ▲ $-25.093M ▲
Q4-2024 $84.71M $74.277M $-34.655M -40.91% $-0.6 $-28.067M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $232.434M ▼ $641.861M ▼ $168.903M ▲ $472.958M ▼
Q3-2025 $250.798M ▼ $643.605M ▲ $165.407M ▲ $478.198M ▲
Q2-2025 $257.147M ▼ $595.615M ▼ $155.507M ▲ $440.108M ▼
Q1-2025 $270.827M ▼ $608.58M ▼ $152.639M ▲ $455.941M ▼
Q4-2024 $276.399M $614.323M $141.634M $472.689M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $20.39M ▲ $-1.4M ▲ $-9.397M ▼ $1.826M ▼ $-9.042M ▲ $-10.565M ▲
Q2-2025 $-39.328M ▼ $-12.986M ▲ $-1.426M ▲ $3.196M ▼ $-11.112M ▼ $-17.13M ▲
Q1-2025 $-31.594M ▲ $-21.428M ▼ $-1.536M ▼ $17.944M ▲ $-5.073M ▲ $-23.696M ▼
Q4-2024 $-34.655M ▲ $-15.32M ▼ $-1.285M ▼ $3.627M ▲ $-12.905M ▼ $-17.322M ▼
Q3-2024 $-85.571M $-6.378M $-711K $2.908M $-4.179M $-7.343M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025Q4-2025
Antibody Discovery
Antibody Discovery
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲
Dna And Biopharma Libraries
Dna And Biopharma Libraries
 $0 ▲$0 ▲$0 ▲$0 ▲
Ngs Tools
Ngs Tools
 $50.00M ▲$50.00M ▲$60.00M ▲$50.00M ▼
Oligo Pools
Oligo Pools
 $10.00M ▲$0 ▼$10.00M ▲$10.00M ▲
Synthetic Genes
Synthetic Genes
 $30.00M ▲$30.00M ▲$30.00M ▲$30.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing steadily each year, showing that demand for Twist’s products is growing and the business is gaining commercial traction. Gross profit has also improved, suggesting the core technology is scaling and production is becoming more efficient. However, the company still runs with sizable operating and net losses, meaning it spends much more on staffing, facilities, R&D, and selling costs than it brings in from sales. Losses have started to narrow a bit recently, but the path to break-even is still ahead of them and will depend on further revenue growth and continued cost discipline.

Balance Sheet

Balance Sheet The balance sheet shows a company with a solid asset base and a meaningful cash cushion, but one that has been drawing down resources over time to fund growth. Total assets and cash peaked a few years ago and have since declined, reflecting ongoing investment and operating losses. Debt is relatively modest compared with the size of the business and the level of equity, so financial leverage does not appear excessive. Shareholders’ equity has been shrinking as losses accumulate, which is a key trend to watch because, if it continued for many years, it would limit the company’s flexibility unless offset by improved profitability or fresh capital.

Cash Flow

Cash Flow Twist is still burning cash from its day‑to‑day operations, although the cash outflow has improved in the most recent year, which hints at better cost control and growing scale. Free cash flow remains negative as the company invests in equipment and facilities, but capital spending has come down sharply from its peak build‑out year, easing some pressure. Overall, the business is not yet self‑funding and continues to rely on its cash reserves (and potentially future financing) to bridge the gap while it pursues growth and moves toward potential profitability.

Competitive Edge

Competitive Edge Twist’s competitive position is built around its silicon‑based DNA synthesis platform, which offers higher throughput, better precision, and lower cost than many traditional methods. This creates a cost and quality edge that is difficult for rivals to replicate quickly. A large portfolio of patents and trade secrets, plus specialized manufacturing know‑how, strengthen its defenses. As customers embed Twist’s products into research workflows, diagnostics development, and regulatory filings, switching away becomes cumbersome and risky, which raises switching costs. The firm is already a major player in synthetic DNA, and scale helps it lower unit costs further, reinforcing its position in genes, oligo pools, NGS enrichment, and antibody discovery.

Innovation and R&D

Innovation and R&D Innovation is the core of Twist’s story. The company has turned a novel silicon‑chip approach into a broad product suite spanning synthetic genes, massive DNA libraries, next‑generation sequencing tools, and antibody discovery services. It continues to push into new areas such as DNA‑based data storage, advanced oncology and liquid biopsy panels, and AI‑enabled antibody design. Investments in the “factory of the future” aim to expand capacity and reduce unit costs over time, while potential expansion into synthetic RNA could open additional markets tied to vaccines and therapeutics. This heavy R&D and infrastructure spending creates clear upside potential but also explains the persistent losses: the business is deliberately front‑loading innovation in hopes of capturing large future markets.

Summary

Twist Bioscience is a high‑growth, high‑investment synthetic biology company with a distinctive technology platform and a broadening product portfolio. Revenue and gross profit are rising at a healthy pace, but the firm is still operating at a meaningful loss and consuming cash, reflecting the cost of scaling manufacturing and aggressively funding R&D. The balance sheet shows moderate debt and a decent cash buffer, but equity has been eroded by repeated losses, underscoring the importance of eventually narrowing the gap between spending and income. Strategically, Twist appears to enjoy a strong technological moat, cost advantages, and sticky customer relationships in attractive markets like genomics, NGS, and biopharma discovery. The main opportunity lies in turning this technological and commercial momentum into a sustainable, profitable business; the main risk is that this transition could take longer, or cost more, than expected while competition and technological change remain intense.

NEWS

November 14, 2025 · 7:15 AM UTC

Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results

Read more

November 3, 2025 · 8:00 AM UTC

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Read more

October 24, 2025 · 6:20 AM UTC

Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights

Read more

October 16, 2025 · 2:32 PM UTC

Kuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law Firm

Read more

October 6, 2025 · 8:00 AM UTC

Twist Bioscience and Element Biosciences Advance Collaboration with Launch of New Trinity Freestyle™ Sequencing Workflow for the AVITI™ System

Read more